Vizz (Aceclidine) Ophthalmic Solution
Vizz is FDA-approved specifically for the treatment of presbyopia in adults, dosed as one drop in each eye, followed by a second drop 2 minutes later, once daily. 1
Indication
Vizz (aceclidine ophthalmic solution 1.44%) is indicated exclusively for presbyopia treatment in adults—not for glaucoma or other ocular conditions. 1 This represents a distinct departure from historical uses of aceclidine, which was previously studied for glaucoma management but showed limited efficacy in that context. 2
Dosing Regimen
The precise dosing protocol is:
- Instill 1 drop in each eye
- Wait exactly 2 minutes
- Instill a second drop in each eye
- Administer once daily
- Use from a single-dose vial and discard after use 1
Critical administration considerations:
- Remove contact lenses before instillation; wait 10 minutes before reinsertion 1
- If using multiple topical ophthalmic products, separate administration by at least 5 minutes 1
- Avoid touching the vial tip to any surface to prevent contamination 1
Contraindications
There are no absolute contraindications listed in the FDA labeling. 1 However, the drug is not recommended in patients with known hypersensitivity to aceclidine or any ingredient in the formulation. 1
Warnings and Precautions
Vision-Related Risks
Blurred vision and accommodative spasm are significant concerns. Patients must be counseled to:
- Not drive or operate machinery if vision is unclear
- Exercise extreme caution with night driving and activities in poor illumination
- Expect temporary dim or dark vision after instillation 1
Retinal Complications
Rare but serious: retinal tears and detachments have been reported with miotic agents. 1
- Mandatory retinal examination before initiating therapy
- Instruct patients to seek immediate care for sudden flashing lights, floaters, or vision loss 1
Iritis History
Miotics can exacerbate sequelae of ocular inflammation, particularly adhesions (synechiae) between iris and lens in patients with prior iritis. Use with caution in this population. 1
Adverse Effects
Most common adverse reactions from Phase 3 trials (466 participants, 42 days; 217 participants, 6 months):
- Instillation site irritation: 20%
- Dim vision: 16%
- Headache: 13%
- Conjunctival hyperemia: 8%
- Ocular hyperemia: 7% 1
The majority of adverse effects were mild, transient, and self-resolving. 1 A 2026 meta-analysis confirmed aceclidine was associated with higher treatment-emergent adverse events compared to placebo (RR 2.23,95% CI 1.61-3.09), but no significant differences in serious adverse events. 3
Efficacy Evidence
Recent high-quality evidence demonstrates robust efficacy: aceclidine significantly increased the likelihood of achieving ≥3-line improvement in distance-corrected near visual acuity compared to placebo (RR 6.28,95% CI 4.22-9.35) in parallel-group trials. 3 Monotherapy may offer slight advantages over combination regimens with brimonidine. 3
Special Populations
Pregnancy (no adequate human studies): Animal studies showed no adverse maternal, fetal, or neonatal effects at clinically relevant doses. 1
Lactation: Systemic levels are low after topical administration; presence in human milk unknown. Consider developmental benefits of breastfeeding against maternal need. 1
Geriatric use: No overall differences in safety or effectiveness observed in patients ≥65 years versus younger adults. 1
Pediatric use: Not applicable—presbyopia does not occur in children. 1
Clinical Pearls
- Aceclidine works as a cholinergic agonist (miotic) 1, producing pupillary constriction that enhances depth of focus
- Unlike historical glaucoma applications where aceclidine showed poor additive effects with timolol 2, its presbyopia indication is well-supported by modern Phase 3 data
- The mechanism involves M3 muscarinic receptor activation 4, though the drug can dissociate accommodative from other responses